Cargando…
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
BACKGROUND: Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) in medically fit patients with R/R AML. METHODS: We...
Autores principales: | Park, Silvia, Kwag, Daehun, Kim, Tong Yoon, Lee, Jong Hyuk, Lee, Joon yeop, Min, Gi June, Park, Sung Soo, Yahng, Seung-Ah, Jeon, Young-Woo, Shin, Seung-Hwan, Yoon, Jae-Ho, Lee, Sung-Eun, Cho, Byung Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, Kim, Hee-Je |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949776/ https://www.ncbi.nlm.nih.gov/pubmed/35340720 http://dx.doi.org/10.1177/20406207221081637 |
Ejemplares similares
-
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022) -
Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023) -
A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023) -
Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
por: Kim, Tong-Yoon, et al.
Publicado: (2022) -
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)